Implementing sentinel lymph node biopsy programs in developing countries: challenges and opportunities.
BACKGROUND
Sentinel lymph node biopsy (SLNB) is the accepted standard of care in early-stage breast cancer and cutaneous melanoma. This technology is accurate for nodal staging and determining the prognosis of these patients. There are several randomized controlled trials confirming the accuracy of this technique and confirming its role in reducing morbidity and improving quality of life. It is also gaining increased acceptance in the management of other solid tumors. Despite the established benefits of SLNB as a minimally invasive approach for nodal staging, the procedure is still underutilized in many developing countries.


METHODS
The Human Health Division of the International Atomic Energy Agency (IAEA) convened advisory meetings with panels of multidisciplinary experts from different backgrounds with the remit to analyze the difficulties encountered by developing countries in establishing a successful SLNB program. The other remit of the panel was to recommend an effective program based on existing evidence that can be adapted and implemented in developing countries. The experience of some members of the panel in the training for this technique in Asia, Latin America, and Africa provided the insight required for the development of a comprehensive and structured program. The panel included recommendations on the technical aspects of the procedure, as well as a comprehensive training program, including theoretical teaching, practical training in surgical skills, laboratories, and hands-on proctored learning. Particular emphasis was placed on in-built quality assurance requirements to ensure that this powerful staging investigation is implemented with the highest possible standard in the management of cancer patients, with the lowest false negative rate.


CONCLUSIONS
It is hoped that this article will be a useful resource for our colleagues planning to establish a SLNB program.
University Department of Surgery, Royal Free and University College London Medical School, London, UK.
Mohammed
M
Keshtgar
John J
JJ
Zaknun
Durre
D
Sabih
Graciela
G
Lago
Charles E
CE
Cox
Stanley P L
SP
Leong
Giuliano
G
Mariani
D001943:Breast Neoplasms / Q000473:pathology / Q000601:surgery; D003906:Developing Countries; D004502:Education, Medical, Continuing / Q000458:organization & administration*; D005260:Female; D006284:Health Plan Implementation / Q000458:organization & administration*; D006801:Humans; D007391:International Cooperation; D008545:Melanoma / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging / Q000379:methods*; D009369:Neoplasms / Q000473:pathology* / Q000601:surgery; D016730:Program Development; D015397:Program Evaluation; D058996:Quality Improvement; D021701:Sentinel Lymph Node Biopsy / Q000193:education / Q000379:methods*; D012878:Skin Neoplasms / Q000473:pathology / Q000601:surgery
J Clin Oncol. 2005 Jul 1;23(19):4312-21
15994144
Ann Oncol. 2005 Nov;16(11):1832-40
16107497
Nucl Med Biol. 2001 Jul;28(5):493-8
11516693
J Natl Cancer Inst. 2006 May 3;98(9):599-609
16670385
Nucl Med Biol. 2003 Nov;30(8):805-10
14698783
J Nucl Med. 2006 Feb;47(2):234-41
16455628
Semin Oncol. 2002 Aug;29(4):361-9
12170439
Ann Surg. 2004 Sep;240(3):462-8; discussion 468-71
15319717
Ann Surg Oncol. 2008 Dec;15(12):3378-83
19097267
Nucl Med Biol. 2003 Jul;30(5):457-64
12831982
Ann Surg. 2005 Sep;242(3):302-11; discussion 311-3
16135917
S Afr Med J. 2000 Dec;90(12):1212-6
11234652
Dermatol Surg. 2005 Mar;31(3):327-30
15841636
J Clin Oncol. 2001 Sep 15;19(18 Suppl):125S-127S
11560987
Asian J Surg. 2004 Oct;27(4):294-8
15564182
Ann Surg Oncol. 2009 Feb;16(2):266-75
19050973
Eur J Cancer. 2009 May;45(8):1381-8
19128957
Lancet Oncol. 2007 Oct;8(10):881-8
17851130
Br J Surg. 2005 Dec;92(12):1494-7
16308853
J Surg Oncol. 2008 Nov 1;98(6):403-6
18683193
N Engl J Med. 2002 Aug 22;347(8):567-75
12192016
Int J Cancer. 2001 Sep 20;95(5):307-12
11494230
Nat Clin Pract Oncol. 2008 Sep;5(9):510-1
18679393
J Nucl Med. 2001 Jun;42(6):951-9
11390562
Eur J Surg Oncol. 2008 May;34(5):508-13
17614245
Surgery. 1999 Oct;126(4):714-20; discussion 720-2
10520920
J Drugs Dermatol. 2007 Jan;6(1):10-6
17373156
Ann Surg Oncol. 2008 Nov;15(11):3252-8
18784961
J Am Coll Surg. 2001 Nov;193(5):473-8
11708502
J Clin Oncol. 2000 Jul;18(13):2560-6
10893287
Ann Surg. 2004 Jun;239(6):828-37; discussion 837-40
15166962
Br J Dermatol. 2006 Sep;155(3):561-9
16911282
Surgery. 2005 Sep;138(3):474-81
16213901
World J Surg Oncol. 2007 Jan 29;5:10
17261174
Virchows Arch. 2006 Mar;448(3):241-7
16362823
Ann Surg. 1991 Oct;214(4):491-9; discussion 499-501
1953101
Eur J Cancer. 2005 Jan;41(2):231-7
15661547
Ann Surg Oncol. 2007 May;14(5):1612-7
17287998
J Clin Oncol. 2005 Oct 20;23(30):7703-20
16157938
Natl Med J India. 2009 Sep-Oct;22(5):234-6
20334043
Int J Clin Oncol. 2008 Feb;13(1):33-41
18307017
N Engl J Med. 2008 Jan 17;358(3):213-6
18199859
Cancer. 2006 Jan 1;106(1):4-16
16329134
BMC Surg. 2009 Jan 27;9:2
19173714
Lancet Oncol. 2002 Feb;3(2):105-10
11905458
Ann Surg. 2008 Apr;247(4):687-93
18362633
Br J Cancer. 2006 Mar 13;94(5):681-5
16495929
Eur J Nucl Med. 2000 Apr;27(4):377-91
10805110
Eur J Cancer. 2004 Dec;40(18):2812-9
15571965
Lancet. 1993 Jun 5;341(8858):1485
8099186
J Clin Oncol. 2009 Feb 10;27(5):726-32
19114697
Ann Surg. 2008 Jan;247(1):136-42
18156933
Br J Surg. 2006 May;93(5):572-6
16550634
Ann Surg. 1999 Oct;230(4):453-63; discussion 463-5
10522715
Arch Surg. 1995 Jan;130(1):88-92
7802583
Eur J Surg Oncol. 2007 Feb;33(1):16-22
17071045